+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Oncology Biosimilars Market Research Report by End-User, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 4968765
  • Report
  • July 2021
  • Region: Global
  • 190 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Oncology Biosimilars Market will Grow to USD 7,652.51 Million by 2026, at a CAGR of 17.91%

FEATURED COMPANIES

  • Amgen
  • Baxter
  • Biocon
  • Cipla
  • Dr Reddy's Laboratories
  • F Hoffmann-la Roche
  • MORE
The Global Oncology Biosimilars Market size was estimated at USD 2,846.49 Million in 2020 and expected to reach USD 3,346.91 Million in 2021, at a Compound Annual Growth Rate (CAGR) 17.91% to reach USD 7,652.51 Million by 2026.



Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Oncology Biosimilars to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on End-User, the Oncology Biosimilars Market was examined across Hospitals and Retail Pharmacies.
  • Based on Application, the Oncology Biosimilars Market was examined across Cancer Treatment Drugs and Supportive Care Drugs.
  • Based on Geography, the Oncology Biosimilars Market was examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas was further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific was further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa was further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. This ongoing research amplifies this research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Oncology Biosimilars Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Oncology Biosimilars Market, including Amgen, Baxter, Biocon, Cipla, Dr Reddy's Laboratories, F Hoffmann-la Roche, Hospira, Pfizer, Sandoz, and Sanofi.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Oncology Biosimilars Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Oncology Biosimilars Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Oncology Biosimilars Market?
4. What is the competitive strategic window for opportunities in the Global Oncology Biosimilars Market?
5. What are the technology trends and regulatory frameworks in the Global Oncology Biosimilars Market?
6. What is the market share of the leading vendors in the Global Oncology Biosimilars Market?
7. What modes and strategic moves are considered suitable for entering the Global Oncology Biosimilars Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen
  • Baxter
  • Biocon
  • Cipla
  • Dr Reddy's Laboratories
  • F Hoffmann-la Roche
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. End-User Outlook
3.4. Application Outlook
3.5. Geography Outlook
3.6. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rapid approval by regulatory authorities for commercialization of products
5.1.1.2. Rising incidence of various types of cancers and leukaemia
5.1.2. Restraints
5.1.2.1. High costs involved in the research
5.1.3. Opportunities
5.1.3.1. Introduction of new and innovative treatment options
5.1.3.2. Recent innovation in clinical drug development
5.1.4. Challenges
5.1.4.1. Limited clinical safety and efficacy data
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Oncology Biosimilars Market, by End-User
6.1. Introduction
6.2. Hospitals
6.3. Retail Pharmacies

7. Oncology Biosimilars Market, by Application
7.1. Introduction
7.2. Cancer Treatment Drugs
7.3. Supportive Care Drugs

8. Americas Oncology Biosimilars Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Oncology Biosimilars Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Thailand

10. Europe, Middle East & Africa Oncology Biosimilars Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Amgen
12.2. Baxter
12.3. Biocon
12.4. Cipla
12.5. Dr Reddy's Laboratories
12.6. F Hoffmann-la Roche
12.7. Hospira
12.8. Pfizer
12.9. Sandoz
12.10. Sanofi

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2020 (USD MILLION)
FIGURE 3. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2020 (USD MILLION)
FIGURE 4. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 5. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 6. GLOBAL ONCOLOGY BIOSIMILARS MARKET: MARKET DYNAMICS
FIGURE 7. GLOBAL ONCOLOGY BIOSIMILARS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 8. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2020 VS 2026 (%)
FIGURE 9. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2020 VS 2026 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2026
FIGURE 11. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY HOSPITALS, 2018-2026 (USD MILLION)
FIGURE 12. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 13. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2026 (USD MILLION)
FIGURE 14. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY RETAIL PHARMACIES, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 15. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (%)
FIGURE 16. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (USD MILLION)
FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2026
FIGURE 18. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY CANCER TREATMENT DRUGS, 2018-2026 (USD MILLION)
FIGURE 19. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY CANCER TREATMENT DRUGS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 20. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2026 (USD MILLION)
FIGURE 21. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 22. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 23. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 24. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 25. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 26. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 27. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 28. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 29. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 30. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 31. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 32. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 33. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 34. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 35. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 36. INDONESIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 37. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 38. MALAYSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 39. PHILIPPINES ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 40. SINGAPORE ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 41. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 42. THAILAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 43. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 44. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 45. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 46. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 47. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 48. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 49. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 50. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 51. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 52. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 53. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 54. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 55. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 56. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 57. GLOBAL ONCOLOGY BIOSIMILARS MARKET: FPNV POSITIONING MATRIX
FIGURE 58. GLOBAL ONCOLOGY BIOSIMILARS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 59. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL ONCOLOGY BIOSIMILARS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 5. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 6. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY RETAIL PHARMACIES, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 7. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 8. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY CANCER TREATMENT DRUGS, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 9. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 10. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 11. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 12. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 13. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 14. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 15. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 16. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 17. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 18. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 19. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 20. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 21. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 22. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 23. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 24. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 25. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 26. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 27. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 28. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 29. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 30. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 31. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 32. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 33. INDONESIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 34. INDONESIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 35. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 36. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 37. MALAYSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 38. MALAYSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 39. PHILIPPINES ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 40. PHILIPPINES ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 41. SINGAPORE ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 42. SINGAPORE ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 43. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 44. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 45. THAILAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 46. THAILAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 47. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 48. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 49. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 50. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 51. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 52. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 53. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 54. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 55. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 56. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 57. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 58. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 59. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 60. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 61. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 62. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 63. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 64. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 65. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 66. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 67. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 68. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 69. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 70. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 71. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 72. GLOBAL ONCOLOGY BIOSIMILARS MARKET: SCORES
TABLE 73. GLOBAL ONCOLOGY BIOSIMILARS MARKET: BUSINESS STRATEGY
TABLE 74. GLOBAL ONCOLOGY BIOSIMILARS MARKET: PRODUCT SATISFACTION
TABLE 75. GLOBAL ONCOLOGY BIOSIMILARS MARKET: RANKING
TABLE 76. GLOBAL ONCOLOGY BIOSIMILARS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 77. GLOBAL ONCOLOGY BIOSIMILARS MARKET: MERGER & ACQUISITION
TABLE 78. GLOBAL ONCOLOGY BIOSIMILARS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 79. GLOBAL ONCOLOGY BIOSIMILARS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 80. GLOBAL ONCOLOGY BIOSIMILARS MARKET: INVESTMENT & FUNDING
TABLE 81. GLOBAL ONCOLOGY BIOSIMILARS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 82. GLOBAL ONCOLOGY BIOSIMILARS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Amgen
  • Baxter
  • Biocon
  • Cipla
  • Dr Reddy's Laboratories
  • F Hoffmann-la Roche
  • Hospira
  • Pfizer
  • Sandoz
  • Sanofi
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll